SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Gabe Fernandez12/3/2004 1:06:30 PM
  Read Replies (1) of 1386
 
Despite the fact that the drug treated groups contained a larger number of more severely injured patients, an analysis of the adverse medical events during the first 10 days post-treatment revealed trends of a lower incidence (p less than 0.2) of mortality (3 vs. 6 patients, or 5.8% vs. 12.2%), fever (88% vs. 98%) and hypotension (19% vs. 33%) in the dexanabinol treated group compared to placebo. (Three more patients in the dexanabinol treated group and one more in the placebo group died later of peripheral complications from other injuries sustained at the time of the brain injury, bringing the total to 6 deaths in the test group, or 11.5%, and 7 deaths in the placebo group, or 14.3%.) ICP management was significantly improved in the dexanabinol group without concomitant reductions in systolic blood pressure. Thus, the mean percentage time with ICP above 25mmHg, a highly negative prognostic factor, was reduced by 60-80% on Days 1-4 post-injury in the dexanabinol treated group compared to placebo. The difference was highly significant (p less than 0.01) on Day 2.

I find this to be a key point in my belief that Dexanabinol will be succesful. The results obtained in Phase II should be able to be better due to the changes in the protocol and the change of GOSE gabe
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News